The provisional patent application covers the composition of matter of Zylorion’s novel psilocybin-based compound, ZYL-314, for the treatment of mental health disorders and other central nervous system conditions and cognitive disorders.
Mr. Jeroen Tas Joins Zylorion as a Strategic Advisor and Observer to the Board of Directors
CALGARY, ALBERTA – January 6, 2022
Announcing Mr. Jeroen Tas has joined the Company as a strategic advisor and will also act as an observer to the Board of Directors.
Zylorion Appoints Members to Newly Formed Scientific and Digital Health Advisory Committees
CALGARY, ALBERTA – December 8, 2021
Announcing the establishment of the Company’s Scientific Advisory Committee and Digital Health Advisory Committee, (collectively the “Committees”), and the appointment of five highly distinguished members to the Committees.
Zylorion Announces Appointments to Executive Leadership Team
CALGARY, ALBERTA – October 25, 2021
An update on key additions to its executive leadership team that have recently taken place over the past quarter.